Partain N, Postlewait LM, Teshome M, et al. - As controversies remain regarding the role of modified radical mastectomy (MRM) in patients with de novo stage IV inflammatory breast cancer (IBC), researchers sought to determine how MRM affects outcomes in these patients. They identified 97 women presenting with stage IV IBC in an institutional database (2007–2016) for inclusion. Initially, chemotherapy was administered to all of these women. MRM was performed on 52 patients (53.6%), and 47 were administered post-mastectomy radiation. Findings from this retrospective study suggested improved OS in de novo stage IV IBC patients in independent correlation with undergoing MRM, providing strong support to the necessity for prospective randomized trials examining possible survival benefits of MRM in de novo stage IV IBC patients. Median overall survival was 19 months in the non-MRM group vs 58 months in the MRM group.